

PRESS RELEASE



February 12th, 2018, Lund, Sweden

Invitation to presentation of Immunovia's Full Year Report 2017 on February 15, 2018

Lund (Sweden) - Immunovia will publish the company's Full Year Report 2017 for the period January – December 2017 on Thursday, February 15, at 08:00 a.m. CET.

Immunovia invites to a teleconference (in English) for investors, analysts and media on February 15, at 4:00 – 5:00 p.m. CET.

Mats Grahn, CEO will present Immunovia and comment on the Full Year Report 2017 followed by a Q&A-session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below from:

Telephone:

SE: +46856642662
CH: +41225675548
UK: +442030089803
DK: +4535445579
US: 18557532235
NO: +4723500254

Germany Toll: +49 (0) 6922224998
PIN: 89565063#

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (<http://immunovia.com/investors/financial-reports/>) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For questions or interview bookings:

ir@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company's Certified Adviser. For more information, please visit www.immunovia.com.

###